Infectious causes of cancer

Alternating Nucleix’s Bladder EpiCheck® With Standard Surveillance Can Reduce Burden on Patients and Healthcare Systems

Retrieved on: 
Wednesday, July 7, 2021
Biotechnology, Managed care, Oncology, General Health, Health, Medical devices, Hospitals, Other Health, Clinical medicine, Medicine, Infectious causes of cancer, Bladder cancer, Branches of biology, Cystoscopy, Urinary bladder, Hexyl aminolevulinate hydrochloride, Bladder EpiCheck®, Nucleix, BLADDER EPICHECK®, NUCLEIX

The analysis, titled Alternating Cystoscopy with Bladder EpiCheck in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model, was published in the peer-reviewed journal Bladder Cancer .

Key Points: 
  • The analysis, titled Alternating Cystoscopy with Bladder EpiCheck in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model, was published in the peer-reviewed journal Bladder Cancer .
  • Researchers developed a decision analysis model to compare standard surveillance with a modified surveillance that alternated between standard methods and use of Bladder EpiCheck every three to six months.
  • Bladder EpiCheck provides patients and clinicians with a simple, objective urine test to detect recurrence of bladder tumors.
  • We are building an EpiCheck franchise, beginning with our Bladder EpiCheck testing kit marketed in Europe for bladder cancer recurrence.

North America HPV Testing and Pap Test Market Potential, Industry Analysis and Forecast Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Women, Other Health, Consumer, Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, Cervical cancer, HPV vaccine, Cervical screening

The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, the growing number of cervical cancer cases may surge the demand for HPV testing and PAP tests, boosting the market growth.
  • Thus, the growing cases of cervical cancer across the North American region are expected to boost the demand for HPV testing and Pap test market over the forthcoming years.
  • The US market dominated the North America HPV Testing Market by Country 2020, thereby, achieving a market value of $844.5 million by 2027.

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

Retrieved on: 
Tuesday, July 6, 2021
Epstein–Barr virus, Infectious causes of cancer, Esperion Therapeutics, EBV, Ivor Royston, Lymphoma, Medical specialties, Health, Clinical medicine, Viral structural proteins

SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.

Key Points: 
  • SAN DIEGO, July 6, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.(Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer.
  • "Ayman is one of the world's leading experts on Epstein-Barr virus (EBV)-associated cancers and a tremendous addition to our management team," said Ivor Royston, M.D., President and Chief Executive Officer of Viracta.
  • Our impressive clinical data has validated the approach, and I am thrilled to have the opportunity to join Viracta as Chief Scientific Officer at this very exciting time.
  • Patric Nelson, MBA,joined Viracta from Esperion Therapeutics, where he served as Vice President, Business Development and Alliance Management.

Prosigna Breast Cancer Gene Signature Test Now Reimbursed in Germany

Retrieved on: 
Tuesday, July 6, 2021
Oncology, Medical devices, Health, Genetics, Pharmaceutical, Biotechnology, Infectious causes of cancer, Cancer, Prostate cancer, Bladder cancer, Clinical medicine, Branches of biology, Health, Biomarkers, Medical genetics, Draft:Veracyte

Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that the Prosigna Breast Cancer Gene Signature Assay is now reimbursed by the statutory health insurances in Germany following a recent decision of the Federal Joint Committee (G-BA).

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that the Prosigna Breast Cancer Gene Signature Assay is now reimbursed by the statutory health insurances in Germany following a recent decision of the Federal Joint Committee (G-BA).
  • This milestone is a victory for those who may potentially benefit from the Prosigna test, said Morten Frost, general manager of pulmonology and breast cancer for Veracyte.
  • The Prosigna test analyzes the activity of 50 genes known as the PAM50 gene signature.
  • The companys tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

Retrieved on: 
Friday, July 2, 2021
Clinical medicine, Medicine, Cancer, DNA, Infectious causes of cancer, Oncology, Anatomical pathology, Circulating tumor DNA, Neoplasms, Natera, Colorectal cancer, Bladder cancer

"We believe that personalized MRD testing is the future and will improve treatment decisions for tens of thousands of colorectal cancer patients in Japan and around the world."

Key Points: 
  • "We believe that personalized MRD testing is the future and will improve treatment decisions for tens of thousands of colorectal cancer patients in Japan and around the world."
  • Longitudinal MRD-positivity was significantly associated with inferior disease-free survival (hazard ratio = 46.8) and Signatera demonstrated a relapse sensitivity of 93.1%.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Global HPV Testing and Pap Test Market Analysis Report and Forecast, 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, PAP

The "Global HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global HPV Testing and Pap Test Market size is expected to reach $7.1 billion by 2027, rising at a market growth of 33.5% CAGR during the forecast period.
  • It is suggested that a woman should undergo a Pap test every 3 years starting from the age of 21.
  • Therefore, the outbreak of COVID-19 pandemic has adversely affected the HPV testing and Pap test market.

VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine

Retrieved on: 
Thursday, July 1, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Medicine, Vaccines, Infectious causes of cancer, Hepatitis B, Hepadnaviridae, Vaccine, Hepatitis, HBsAg, Hepatitis D, CPT® Codes, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., CPT® CODES, HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

If approved, VBIs 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines.

Key Points: 
  • If approved, VBIs 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines.
  • VBIs vaccine candidate is the only 3-antigen hepatitis B vaccine, comprised of the S, pre-S1, and pre-S2 surface antigens of the hepatitis B virus, and is approved for use and commercially-available in Israel.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).

Birmingham University and Nonacus Partner to Develop Urine Test for Bladder Cancer

Retrieved on: 
Thursday, July 1, 2021
Technology, Genetics, Software, Biotechnology, Health, University, Data management, Education, Oncology, Clinical medicine, Medicine, Branches of biology, Infectious causes of cancer, Aging-associated diseases, Bladder cancer, Biopsy, Cancer, Urinary bladder, Urinary retention, Renal biopsy, Cystoscopy

Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer.

Key Points: 
  • Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive test for bladder cancer.
  • In the UK, over 100,000 people a year are referred to hospital clinics that investigate for bladder cancer, usually after passing blood in their urine (haematuria).
  • Of these 100,000 patients, around 12% are subsequently diagnosed with bladder cancer, normally after a second invasive procedure to extract a biopsy.
  • Nonacus intends to launch the new bladder cancer test within 12 months, and the final product will include access to bioinformatics software to help with analysis.

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) for the Treatment of Trichomoniasis

Retrieved on: 
Thursday, July 1, 2021
Medical specialties, Infectious diseases, Sexually transmitted diseases and infections, Antiprotozoal agents, Nitroimidazole antibiotics, Clinical medicine, Infectious causes of cancer, Bacterial vaginosis, Mycoplasma, Trichomoniasis, Secnidazole

[1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.

Key Points: 
  • [1] SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women.
  • The supplemental approval makes SOLOSEC the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.
  • Research demonstrates that approximately 70% of women with trichomoniasis are PCR positive for BV,[2]" said Jon Stelzmiller, President Specialty, Lupin Pharmaceuticals, Inc.
  • SOLOSEC(secnidazole) 2 g oral granules is an antimicrobial agent indicatedfor the treatment of BV in adult women and trichomoniasis in adults.

Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers

Retrieved on: 
Tuesday, June 29, 2021
Cancer, Clinical medicine, Neoplasms, Infectious causes of cancer, Virotherapy, KRAS, Cancer immunotherapy, PDAC, Pancreatic cancer, Immunotherapy, Adenocarcinoma, Carcinoma

AMPLIFY-201 is a Phase 1/2 clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer, or CRC, or pancreatic ductal adenocarcinoma, or PDAC.

Key Points: 
  • AMPLIFY-201 is a Phase 1/2 clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer, or CRC, or pancreatic ductal adenocarcinoma, or PDAC.
  • Following an initial dose escalation phase, we intend to evaluate the potential of ELI-002 as a treatment for a number of KRAS-mutated cancers.
  • Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.